The Lighthouse

The Lighthouse On Curing Cancer

By Erik Zimerman On June 16, 2013 · 5 Comments · In The Jackal's Den, The Whiskey Room

Nearly a decade and a half ago, when first starting my Biochemistry Major, I was happily surprised to see that the then newly found knowledge and scientific techniques almost necessarily seemed to spell the end of at least many types of cancer. A foregone conclusion, I remembered thinking…. Quite a few years later, I am very surprised about the lack of progress made along the fascinating track I had envisioned. Needless to say, people continue to die from the ignoble disease. Therefore, it is time to put this concept to paper, enlighten a few people, and perhaps get feedback from experts on what technicalities are holding up the shooting of Paris’ arrow into cancer’s Achilles’ heel. The casual (non scientist) reader will likely find the true nature of cancer and its most logical solution surprising and fascinating; as its true nature is so different from what is most often portrayed. In first order of course, is an understanding of What Is cancer… The disease’s most broad definition sets it apart from almost all other human diseases. Generally speaking, most human diseases can be categorized in two broad groups; those that are pathogenic, and those that are not. A pathogenic disease is pretty straightforward, and as is well known today, caused [...]

[Continue Reading...]

Lighthouse Stock Tip Update – Amarin Script Sales

By Erik Zimerman On March 7, 2013 · 7 Comments · In The Whiskey Room

A few months back, one of my updates suggested CEL and AMRN as short term/medium term investments. In the case of CEL, the market had overreacted to new competition in the Israeli market and investors with our suggested timing were repaid with an approximate 69% return. In Amarin’s case (Amarin Corporation Plc, NASDAQ: AMRN), though the stock continued to rise after our endorsement, and providing a 30% return shorty thereafter, I suggested holding on to this position still further. Since Amarin’s announcement to “Go it Alone” in launching their Marine indication for Vascepa, and continuous FDA delays in reaching a regulatory exclusivity decision (NCE), Amarin has continued to lose value; now well below our suggested entry point. Some decrease, based on the the uncertainty of smaller companies launching new drugs successively and lack of acquisition or marketing partner (did they know something we did not? or was the CEO simply holding for too high a bid?) was quite logical. In fact, merger speculation had largely helped fuel Amarin’s rapid increase in share price. Though management so far seems to have been more than competent in achieving their goals and milestones they did fail miserably during this period of rapid share value loss in communicating with their investors. This gave fuel [...]

[Continue Reading...]

S	M	T	W	T	F	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30

The Lighthouse On Curing Cancer

Lighthouse Stock Tip Update – Amarin Script Sales

Recent Posts

Top Posts & Pages

Halls

Archives

Subscribe to Blog via Email

The Lighthouse On Curing Cancer

Lighthouse Stock Tip Update – Amarin Script Sales

Recent Posts

Top Posts & Pages

Tags

Halls

Archives

Subscribe to Blog via Email